Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) EBT Margin (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed EBT Margin for 16 consecutive years, with 336.83% as the latest value for Q4 2025.

  • Quarterly EBT Margin fell 17880.0% to 336.83% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 30.77% through Dec 2025, down 178.0% year-over-year, with the annual reading at 30.77% for FY2025, 178.0% down from the prior year.
  • EBT Margin hit 336.83% in Q4 2025 for Ironwood Pharmaceuticals, down from 55.73% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 67.41% in Q4 2022 to a low of 1002.24% in Q2 2023.
  • Historically, EBT Margin has averaged 44.14% across 5 years, with a median of 41.93% in 2025.
  • Biggest five-year swings in EBT Margin: tumbled -105755bps in 2023 and later soared 102223bps in 2024.
  • Year by year, EBT Margin stood at 39.49% in 2021, then surged by 71bps to 67.41% in 2022, then crashed by -62bps to 25.83% in 2023, then tumbled by -712bps to 158.04% in 2024, then plummeted by -113bps to 336.83% in 2025.
  • Business Quant data shows EBT Margin for IRWD at 336.83% in Q4 2025, 55.73% in Q3 2025, and 44.37% in Q2 2025.